McKenzie C. Ferguson

McKenzie C. Ferguson

Auto-generated profile, based on publicly available information

McKenzie C. Ferguson

Department of Pharmacy Practice, Southern Illinois University Edwardsville, Edwardsville, IL, United States

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2015 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
EMEwan D McNicol
Ewan D McNicol
MFMcKenzie C Ferguson
McKenzie C Ferguson
JHJana Hudcova
Jana Hudcova

1 December 2018 in The Journal of Pain
Verified
Journal Article
Closed access
RTRaymond C. Tait
Raymond C. Tait
KZKim Zoberi
Kim Zoberi
MFMcKenzie Ferguson
McKenzie Ferguson
KLKimberly Levenhagen
Kimberly Levenhagen
RLRebecca A. Luebbert
Rebecca A. Luebbert
CHChristopher Herndon
Christopher Herndon

23 May 2016 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
EMEwan D McNicol
Ewan D McNicol
MFMcKenzie C Ferguson
McKenzie C Ferguson
SHSimon Haroutounian
Simon Haroutounian
DCDaniel B Carr
Daniel B Carr
RSRoman Schumann
Roman Schumann

18 August 2020 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
PDF file
KEKristin Engelhardt
Kristin Engelhardt
MFMcKenzie Ferguson
McKenzie Ferguson
JRJennifer L. Rosselli
Jennifer L. Rosselli
Objective: To review the incidence, risk factors, prevention, and management of genital mycotic infections (GMIs) associated with sodium-glucose cotransporter 2 (SGLT2) inhibitors. Data Sources: A literature search of PubMed and Reactions Weekly was performed in February 2020 with updated searches monthly through July 2020 to identify relevant data regarding SGLT2 inhibitors and GMIs. Manufacturers of each agent were contacted, and clinical practice guidelines were consulted. Study Selection and Data Extraction: All available literature was evaluated for inclusion based on relevance to the research question, timeliness of the publication, validity, and impact on current practice. A date limit was not set; however, publications from 2010 to July 2020 were prioritized. Data Synthesis: The 3- to 4-fold increased incidence of GMIs is considered a classwide effect of SGLT2 inhibitors. Female sex and a prior history of GMIs are factors associated with the highest risk, whereas circumcised males are at the lowest risk of SGLT2 inhibitor–induced GMI. Personal hygiene advice can reduce the infection risk. When candidiasis occurs, it is often mild and responsive to treatment and often does not require discontinuation of the medication. Relevance to Patient Care and Clinical Practice: This narrative review can assist in shared decision-making discussions with patients who may benefit from SGLT2 inhibitors and provides guidance for health care professionals managing SGLT2 inhibitor–associated GMIs. Conclusions: SGLT2 inhibitors predispose patients to developing mild GMIs. Strong consideration should be given to avoid SGLT2 inhibitors in female patients with a history of severe, recurrent infections. Preventive strategies are optimized diabetes management and personal hygiene advice.

18 January 2021 in Pain
Verified
Journal Article
Open access
NKNathaniel Katz
Nathaniel Katz
RDRobert H. Dworkin
Robert H. Dworkin
RNRichard North
Richard North
STSimon Thomson
Simon Thomson
SESam S. Eldabe
Sam S. Eldabe
LVLalit Venkatesan
Lalit Venkatesan
Spinal cord stimulation (SCS) is an interventional nonpharmacologic treatment used for chronic pain and other indications. Methods for evaluating the safety and efficacy of SCS have evolved from uncontrolled and retrospective studies to prospective randomized controlled trials (RCTs). Although randomization overcomes certain types of bias, additional challenges to the validity of RCTs of SCS include blinding, choice of control groups, nonspecific effects of treatment variables (eg, paresthesia, device programming and recharging, psychological support, and rehabilitative techniques), and safety considerations. To address these challenges, 3 professional societies (Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials, Institute of Neuromodulation, and International Neuromodulation Society) convened a meeting to develop consensus recommendations on the design, conduct, analysis, and interpretation of RCTs of SCS for chronic pain. This article summarizes the results of this meeting. Highlights of our recommendations include disclosing all funding source and potential conflicts; incorporating mechanistic objectives when possible; avoiding noninferiority designs without internal demonstration of assay sensitivity; achieving and documenting double-blinding whenever possible; documenting investigator and site experience; keeping all information provided to patients balanced with respect to expectation of benefit; disclosing all information provided to patients, including verbal scripts; using placebo/sham controls when possible; capturing a complete set of outcome assessments; accounting for ancillary pharmacologic and nonpharmacologic treatments in a clear manner; providing a complete description of intended and actual programming interactions; making a prospective ascertainment of SCS-specific safety outcomes; training patients and researchers on appropriate expectations, outcome assessments, and other key aspects of study performance; and providing transparent and complete reporting of results according to applicable reporting guidelines.

1 March 2015 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
MFMcKenzie Ferguson
McKenzie Ferguson
MLMin Liu
Min Liu